Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:FBIO NASDAQ:IDYA NASDAQ:MNPR NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$18.13+4.7%$15.38$8.04▼$25.88$492.32M2.39473,552 shs411,791 shsFBIOFortress Biotech$3.55-8.7%$2.29$1.33▼$3.97$105.63M1.61383,897 shs993,835 shsIDYAIDEAYA Biosciences$24.53-0.3%$23.94$13.45▼$37.80$2.15B0.121.16 million shs716,755 shsMNPRMonopar Therapeutics$54.49+10.7%$39.33$3.65▼$54.54$336.20M1.239,682 shs43,702 shsOVIDOvid Therapeutics$1.28+1.6%$0.80$0.24▼$1.47$91.02M0.341.03 million shs874,502 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%-2.97%-11.09%+34.58%-16.53%FBIOFortress Biotech0.00%+4.85%+83.49%+111.41%+97.46%IDYAIDEAYA Biosciences0.00%-9.39%+1.15%+9.92%-34.30%MNPRMonopar Therapeutics0.00%+11.33%+37.83%+43.83%+1,175.13%OVIDOvid Therapeutics0.00%+2.44%+29.90%+333.59%+5.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$18.13+4.7%$15.38$8.04▼$25.88$492.32M2.39473,552 shs411,791 shsFBIOFortress Biotech$3.55-8.7%$2.29$1.33▼$3.97$105.63M1.61383,897 shs993,835 shsIDYAIDEAYA Biosciences$24.53-0.3%$23.94$13.45▼$37.80$2.15B0.121.16 million shs716,755 shsMNPRMonopar Therapeutics$54.49+10.7%$39.33$3.65▼$54.54$336.20M1.239,682 shs43,702 shsOVIDOvid Therapeutics$1.28+1.6%$0.80$0.24▼$1.47$91.02M0.341.03 million shs874,502 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%-2.97%-11.09%+34.58%-16.53%FBIOFortress Biotech0.00%+4.85%+83.49%+111.41%+97.46%IDYAIDEAYA Biosciences0.00%-9.39%+1.15%+9.92%-34.30%MNPRMonopar Therapeutics0.00%+11.33%+37.83%+43.83%+1,175.13%OVIDOvid Therapeutics0.00%+2.44%+29.90%+333.59%+5.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57178.81% UpsideFBIOFortress Biotech 3.00Buy$16.50362.06% UpsideIDYAIDEAYA Biosciences 2.81Moderate Buy$42.8574.65% UpsideMNPRMonopar Therapeutics 3.00Buy$71.7532.27% UpsideOVIDOvid Therapeutics 3.17Buy$3.10142.19% UpsideCurrent Analyst Ratings BreakdownLatest OVID, IDYA, FBIO, MNPR, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$87.009/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.009/9/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.009/9/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$45.009/9/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/9/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$87.009/8/2025IDYAIDEAYA BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$36.009/4/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform9/4/2025IDYAIDEAYA BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$41.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$109.80M4.49N/AN/A$8.90 per share2.04FBIOFortress Biotech$59.30M1.79N/AN/A($0.06) per share-59.52IDYAIDEAYA Biosciences$7M307.15N/AN/A$12.25 per share2.00MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/AOVIDOvid Therapeutics$570K159.69N/AN/A$0.96 per share1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)FBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)Latest OVID, IDYA, FBIO, MNPR, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.713.94%N/AN/A N/AFBIOFortress BiotechN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90FBIOFortress Biotech1.341.921.70IDYAIDEAYA BiosciencesN/A12.3912.39MNPRMonopar TherapeuticsN/A33.9333.93OVIDOvid Therapeutics0.234.724.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%FBIOFortress Biotech96.51%IDYAIDEAYA Biosciences98.29%MNPRMonopar Therapeutics1.83%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%FBIOFortress Biotech27.90%IDYAIDEAYA Biosciences2.50%MNPRMonopar Therapeutics20.50%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableFBIOFortress Biotech17029.76 million21.45 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableOVID, IDYA, FBIO, MNPR, and ARCT HeadlinesRecent News About These CompaniesOvid Therapeutics (NASDAQ:OVID) Receives $3.10 Average Price Target from AnalystsSeptember 10, 2025 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ovid TherapeuticsAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Invests $208,000 in Ovid Therapeutics $OVIDAugust 28, 2025 | marketbeat.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 24, 2025 | finance.yahoo.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 23, 2025 | insidermonkey.comOvid Therapeutics (NASDAQ:OVID) Short Interest Up 54.8% in JulyAugust 22, 2025 | marketbeat.comSpotlight On 3 Promising Penny Stocks With Over $60M Market CapAugust 20, 2025 | uk.finance.yahoo.comWilliam Blair Predicts Higher Earnings for Ovid TherapeuticsAugust 19, 2025 | marketbeat.comQ3 EPS Estimates for Ovid Therapeutics Increased by B. RileyAugust 19, 2025 | marketbeat.comWedbush Research Analysts Lower Earnings Estimates for OVIDAugust 19, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSAugust 17, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comOvid Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 16, 2025 | finance.yahoo.comOvid Therapeutics Reports Increased Revenue Amid ChallengesAugust 14, 2025 | msn.comOvid Therapeutics Navigates FDA Disruptions and Government ChallengesAugust 14, 2025 | tipranks.comOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy RatingAugust 13, 2025 | tipranks.comOvid Therapeutics initiated with a Buy at Lucid CapitalAugust 13, 2025 | msn.comOvid Therapeutics Transfers Stock to Nasdaq Capital MarketAugust 13, 2025 | msn.comOvid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comOvid Therapeutics Reports Business Updates and Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Exposure Without the Hype: 3 ETFs That Offer Smarter AI BetsBy Nathan Reiff | August 25, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025OVID, IDYA, FBIO, MNPR, and ARCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$18.13 +0.81 (+4.68%) Closing price 04:00 PM EasternExtended Trading$18.20 +0.07 (+0.39%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Fortress Biotech NASDAQ:FBIO$3.55 -0.34 (-8.74%) Closing price 04:00 PM EasternExtended Trading$3.58 +0.04 (+0.99%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.IDEAYA Biosciences NASDAQ:IDYA$24.53 -0.08 (-0.33%) Closing price 04:00 PM EasternExtended Trading$24.54 +0.02 (+0.06%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Monopar Therapeutics NASDAQ:MNPR$54.49 +5.27 (+10.71%) Closing price 04:00 PM EasternExtended Trading$54.24 -0.25 (-0.45%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Ovid Therapeutics NASDAQ:OVID$1.28 +0.02 (+1.59%) Closing price 04:00 PM EasternExtended Trading$1.27 -0.01 (-0.78%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
